Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer, October 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 157 articles:
HTML format


 

Single Articles


  1. PPARG-Activated Bladder Cancer Cells Exhibit a PPARG Dependency.
    Cancer Discov. 2017 Sep 29. doi: 10.1158/2159-8290.CD-RW2017.
    Abstract    

    Abstract available

  2. HAGGSTROM C, Liedberg F, Hagberg O, Aljabery F, et al
    Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe).
    BMJ Open. 2017;7:e016606.
    Abstract    

    Abstract available

  3. DEMATEI A, Fernandes R, Soares R, Alves H, et al
    Angiogenesis in Schistosoma haematobium-associated urinary bladder cancer.
    APMIS. 2017 Sep 28. doi: 10.1111/apm.12756.
    Abstract    

    Abstract available

  4. LIU Z, Ha US, Yu K, Wu C, et al
    Kavalactone yangonin induces autophagy and sensitizes bladder cancer cells to flavokawain A and docetaxel via inhibition of the mTOR pathway.
    J Biomed Res. 2017;31:408-418.
    Abstract    

    Abstract available

  5. GOSNELL ME, Polikarpov DM, Goldys EM, Zvyagin AV, et al
    Computer-assisted cystoscopy diagnosis of bladder cancer.
    Urol Oncol. 2017 Sep 25. pii: S1078-1439(17)30460.
    Abstract    

    Abstract available

  6. ZHANG M, Ren B, Li Z, Niu W, et al
    Expression of N-Myc Downstream-Regulated Gene 2 in Bladder Cancer and Its Potential Utility as a Urinary Diagnostic Biomarker.
    Med Sci Monit. 2017;23:4644-4649.
    Abstract    

    Abstract available

  7. KOMYAKOV BK, Sergeev AV, Fadeev VA, Ismailov KI, et al
    [Concomitant oncopathological changes in the prostate of urinary bladder cancer patients undergoing radical cystoprostateectomy].
    Urologiia. 2017;:42-45.
    Abstract    

    Abstract available

  8. NASR R, Temraz S, Mukherji D, Shamseddine A, et al
    Distribution and Role of N-acetyltransferase 2 Genetic Polymorphisms in Bladder Cancer Risk in a Lebanese Population
    Asian Pac J Cancer Prev. 2017;18:2561-2568.
    Abstract    

    Abstract available

  9. ASAI A, Miyata Y, Takehara K, Kanda S, et al
    Pathological significance and prognostic significance of FES expression in bladder cancer vary according to tumor grade.
    J Cancer Res Clin Oncol. 2017 Sep 26. doi: 10.1007/s00432-017-2524.
    Abstract    

    Abstract available

  10. WALKER M, Doiron RC, French SD, Feldman-Stewart D, et al
    Bladder-sparing Radiotherapy for Muscle-invasive Bladder Cancer: A Qualitative Study to Identify Barriers and Enablers.
    Clin Oncol (R Coll Radiol). 2017 Sep 23. pii: S0936-6555(17)30396.
    Abstract    

    Abstract available

  11. WU P, Liu S, Su J, Chen J, et al
    Apoptosis triggered by isoquercitrin in bladder cancer cells by activating the AMPK-activated protein kinase pathway.
    Food Funct. 2017 Sep 26. doi: 10.1039/c7fo00778.
    Abstract    

    Abstract available

  12. MA Y, Luo W, Bunch BL, Pratt RN, et al
    1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR-101-3p.
    Oncotarget. 2017;8:60080-60093.
    Abstract    

    Abstract available

  13. GHEIBI P, Zeng S, Son KJ, Vu T, et al
    Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells.
    Sci Rep. 2017;7:12277.
    Abstract    

    Abstract available

  14. RIEKEN M, Shariat SF, Kluth L, Crivelli JJ, et al
    Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer.
    Urol Oncol. 2017 Sep 22. pii: S1078-1439(17)30461.
    Abstract    

    Abstract available

  15. WANG J, Ma W, Liu Y
    Long non-coding RNA HULC promotes bladder cancer cells proliferation but inhibits apoptosis via regulation of ZIC2 and PI3K/AKT signaling pathway.
    Cancer Biomark. 2017 Sep 15. doi: 10.3233/CBM-170188.
    Abstract    

    Abstract available

  16. SHEN L, Zhang F, Huang R, Yan J, et al
    Honokiol inhibits bladder cancer cell invasion through repressing SRC-3 expression and epithelial-mesenchymal transition.
    Oncol Lett. 2017;14:4294-4300.
    Abstract    

    Abstract available

  17. CHANG Y, Xu J, Zhang Q
    Microplate magnetic chemiluminescence immunoassay for detecting urinary survivin in bladder cancer.
    Oncol Lett. 2017;14:4043-4052.
    Abstract    

    Abstract available

  18. PATKAR S, Ostwal V, Ramaswamy A, Engineer R, et al
    Emerging role of multimodality treatment in gall bladder cancer: Outcomes following 510 consecutive resections in a tertiary referral center.
    J Surg Oncol. 2017 Sep 20. doi: 10.1002/jso.24837.
    Abstract    

    Abstract available

  19. ZHANG Z, Fan W, Deng Q, Tang S, et al
    The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies.
    Oncotarget. 2017;8:59527-59538.
    Abstract    

    Abstract available

  20. AVELLINI C, Licini C, Lazzarini R, Gesuita R, et al
    The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer.
    Oncotarget. 2017;8:58642-58653.
    Abstract    

    Abstract available

  21. GEERDES-FENGE HF, Stubbe F, Lobermann M, Warnke P, et al
    [BCGitis with Involvement of Lung, Liver and Bone Marrow after Immunotherapy of Urothelial Cancer].
    Dtsch Med Wochenschr. 2017;142:1375-1378.
    Abstract    

    Abstract available

  22. SOLANKI AA, Martin B, Korpics M, Small C, et al
    Bladder-Preserving Therapy Patterns of Care: A Survey of US Radiation Oncologists.
    Int J Radiat Oncol Biol Phys. 2017;99:383-387.
    Abstract    

    Abstract available

  23. ANNAN AC, Stevens KA, Osunkoya AO
    Urothelial carcinoma involving the ureteral orifice: a clinicopathologic analysis of 93 cases.
    Hum Pathol. 2017;65:101-106.
    Abstract    

    Abstract available

  24. WARSCHKOW R, Guller U, Cerny T, Schmied BM, et al
    Secondary malignancies after rectal cancer resection with and without radiation therapy: A propensity-adjusted, population-based SEER analysis.
    Radiother Oncol. 2017;123:139-146.
    Abstract    

    Abstract available

  25. BERRY A, Iriart X, Fillaux J, Magnaval JF, et al
    [Urinary schistosomiasis and cancer].
    Bull Soc Pathol Exot. 2017;110:68-75.
    Abstract    

    Abstract available

  26. THAM SM, Esuvaranathan K, Mahendran R
    A Murine Orthotopic Bladder Tumor Model and Tumor Detection System.
    J Vis Exp. 2017;.
    Abstract    

    Abstract available

  27. SUTOH YONEYAMA M, Tobisawa Y, Hatakeyama S, Sato M, et al
    A mechanism for evasion of CTL immunity by altered O-glycosylation of HLA class I.
    J Biochem. 2017;161:479-492.
    Abstract    

    Abstract available

  28. CHUANG YW, Yu MC, Huang ST, Yang CK, et al
    Spironolactone and the risk of urinary tract cancer in patients with hypertension: a nationwide population-based retrospective case-control study.
    J Hypertens. 2017;35:170-177.
    Abstract    

    Abstract available

  29. PASCIUTI K, Kuthpady S, Anderson A, Best B, et al
    Bladder radiotherapy treatment: A retrospective comparison of 3-dimensional conformal radiotherapy, intensity-modulated radiation therapy, and volumetric-modulated arc therapy plans.
    Med Dosim. 2017;42:1-6.
    Abstract    

    Abstract available

  30. WARRICK JI
    Clinical Significance of Histologic Variants of Bladder Cancer.
    J Natl Compr Canc Netw. 2017;15:1268-1274.
    Abstract    

    Abstract available

  31. SPIESS PE, Agarwal N, Bangs R, Boorjian SA, et al
    Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
    J Natl Compr Canc Netw. 2017;15:1240-1267.
    Abstract    

    Abstract available

  32. PENCE S, Ozbek E, Ozan Tiryakioglu N, Ersoy Tunali N, et al
    rs3918242 variant genotype frequency and increased TIMP-2 and MMP-9 expression are positively correlated with cancer invasion in urinary bladder cancer.
    Cell Mol Biol (Noisy-le-grand). 2017;63:46-52.
    Abstract    

    Abstract available

  33. LATOSINSKA A, Frantzi M, Vlahou A, Merseburger AS, et al
    Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.
    Proteomics Clin Appl. 2017 Oct 5. doi: 10.1002/prca.201700074.
    Abstract    

    Abstract available

  34. TILLEY SK, Kim WY, Fry RC
    Analysis of bladder cancer tumor CpG methylation and gene expression within The Cancer Genome Atlas identifies GRIA1 as a prognostic biomarker for basal-like bladder cancer.
    Am J Cancer Res. 2017;7:1850-1862.
    Abstract    

    Abstract available

  35. TERVAHARTIALA M, Taimen P, Mirtti T, Koskinen I, et al
    Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer.
    Sci Rep. 2017;7:12682.
    Abstract    

    Abstract available


  36. Targeting Angiogenesis in Bladder Cancer.
    Cancer Discov. 2017 Oct 4. doi: 10.1158/2159-8290.CD-NB2017.
    Abstract    

    Abstract available

  37. KIM YJ, Byun SJ, Ahn H, Kim CS, et al
    Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis.
    Oncotarget. 2017;8:68996-69004.
    Abstract    

    Abstract available

  38. YANG J, Liu Y, He A, Liu Y, et al
    Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B.
    Oncotarget. 2017;8:68721-68729.
    Abstract    

    Abstract available

  39. WANG X, Cui MM, Xu Y, Liu L, et al
    Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer.
    Oncotarget. 2017;8:68115-68122.
    Abstract    

    Abstract available

  40. SONG Y, Zhang P, Sun Y, Li X, et al
    AMPK activation-dependent autophagy compromises oleanolic acid-induced cytotoxicity in human bladder cancer cells.
    Oncotarget. 2017;8:67942-67954.
    Abstract    

    Abstract available

  41. MONTANO R, Khan N, Hou H, Seigne J, et al
    Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor.
    Oncotarget. 2017;8:67754-67768.
    Abstract    

    Abstract available

  42. YUAN D, Zheng S, Wang L, Li J, et al
    MiR-200c inhibits bladder cancer progression by targeting lactate dehydrogenase A.
    Oncotarget. 2017;8:67663-67669.
    Abstract    

    Abstract available

  43. PICHLER R, Heidegger I, Fritz J, Danzl M, et al
    PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy.
    Oncotarget. 2017;8:66849-66864.
    Abstract    

    Abstract available

  44. LI H, Xu Y, Li H
    CD147 as a novel biomarker for predicting the prognosis and clinicopathological features of bladder cancer: a meta-analysis.
    Oncotarget. 2017;8:62573-62588.
    Abstract    

    Abstract available

  45. XIE Y, Li P, Gao Y, Gu L, et al
    Reduced E-cadherin expression is correlated with poor prognosis in patients with bladder cancer: a systematic review and meta-analysis.
    Oncotarget. 2017;8:62489-62499.
    Abstract    

    Abstract available

  46. LIU Q, Diao R, Feng G, Mu X, et al
    Risk score based on three mRNA expression predicts the survival of bladder cancer.
    Oncotarget. 2017;8:61583-61591.
    Abstract    

    Abstract available

  47. HAMANO I, Hatakeyama S, Iwamurau H, Fujita N, et al
    Preoperative chronic kidney disease predicts poor oncological outcomes after radical cystectomy in patients with muscle-invasive bladder cancer.
    Oncotarget. 2017;8:61404-61414.
    Abstract    

    Abstract available

  48. HUANG Y, Fang C, Shi JW, Wen Y, et al
    Identification of hMex-3A and its effect on human bladder cancer cell proliferation.
    Oncotarget. 2017;8:61215-61225.
    Abstract    

    Abstract available

  49. THOMA C
    Bladder cancer: Drug sequencing in metastatic disease.
    Nat Rev Urol. 2017 Oct 4. doi: 10.1038/nrurol.2017.
    Abstract    



  50. WALKER M, French SD, Doiron RC, Brennan K, et al
    Bladder-sparing radiotherapy for muscle-invasive bladder cancer: A survey of providers to determine barriers and enablers.
    Radiother Oncol. 2017 Sep 30. pii: S0167-8140(17)32561.
    Abstract    

    Abstract available

  51. TANAKA T, Koie T, Ohyama C, Hashimoto Y, et al
    Incidental prostate cancer in patients with muscle-invasive bladder cancer who underwent radical cystoprostatectomy.
    Jpn J Clin Oncol. 2017 Aug 18:1-5. doi: 10.1093.
    Abstract    

    Abstract available

  52. GEDERAAS OA, Johnsson A, Berg K, Manandhar R, et al
    Photochemical internalization in bladder cancer - development of an orthotopic in vivo model.
    Photochem Photobiol Sci. 2017 Oct 3. doi: 10.1039/c7pp00176.
    Abstract    

    Abstract available

  53. LAVDANITI M, Zyga S
    Quality of Life in Elderly Bladder Cancer Patients Following a Cystectomy.
    Adv Exp Med Biol. 2017;989:297-300.
    Abstract    

    Abstract available

  54. FARZANEH F, Mehrparvar AH, Lotfi MH
    Occupations and the Risk of Bladder Cancer in Yazd Province: A Case-Control Study.
    Int J Occup Environ Med. 2017;8:191-198.
    Abstract    

    Abstract available

  55. DUEX JE, Swain KE, Dancik GM, Paucek RD, et al
    Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer.
    Mol Cancer Res. 2017 Oct 2. pii: molcanres.0260.2017.
    Abstract    

    Abstract available

  56. BI H, Zhang Z, Guo L, Fu C, et al
    Effect of wound fluid on chemotherapy sensitivity of T24 bladder cancer cells with different enhancer of zeste homolog 2 status.
    Oncotarget. 2017;8:63258-63264.
    Abstract    

    Abstract available

  57. FAN B, Zhang X, Ma Y, Zhang A, et al
    Fangchinoline Induces Apoptosis, Autophagy and Energetic Impairment in Bladder Cancer.
    Cell Physiol Biochem. 2017;43:1003-1011.
    Abstract    

    Abstract available

  58. HE X, Ping J, Wen D
    MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C.
    Exp Ther Med. 2017;14:3253-3258.
    Abstract    

    Abstract available

  59. SONG M, Glasgow M, Murugan P, Rivard C, et al
    Aggressive Angiomyxoma of the Vulva and Bladder.
    Obstet Gynecol. 2017;130:885-888.
    Abstract    

    Abstract available

  60. RADAN M, Carev I, Tesevic V, Politeo O, et al
    Qualitative HPLC-DAD/ESI-TOF-MS Analysis, Cytotoxic, and Apoptotic Effects of Croatian Endemic Centaurea ragusina L. Aqueous Extracts.
    Chem Biodivers. 2017;14.
    Abstract    

    Abstract available

  61. JENSEN BT, Kiesbye B, Soendergaard I, Jensen JB, et al
    Efficacy of preoperative uro-stoma education on self-efficacy after Radical Cystectomy; secondary outcome of a prospective randomized controlled trial.
    Eur J Oncol Nurs. 2017;28:41-46.
    Abstract    

    Abstract available

  62. LEEMAN M, Burgers P, Brehm V, van Brussel JP, et al
    Psoas abscess after bacille Calmette-Guerin instillations causing iliac artery contained rupture.
    J Vasc Surg. 2017;66:1236-1238.
    Abstract    

    Abstract available

  63. BAUR B, Bozdag S
    ProcessDriver: A computational pipeline to identify copy number drivers and associated disrupted biological processes in cancer.
    Genomics. 2017;109.
    Abstract    

    Abstract available

  64. FOX MD, Xiao L, Zhang M, Kamat AM, et al
    Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases.
    Am J Clin Pathol. 2017;147:500-506.
    Abstract    

    Abstract available

  65. SCHIFFMANN J, Sun M, Gandaglia G, Tian Z, et al
    Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)-medicare database.
    Minerva Urol Nefrol. 2017;69:173-180.
    Abstract    

    Abstract available

  66. CORONA MONTES VE, Pastore AL, Gausa L, Rodriguez-Faba O, et al
    Robot assisted retroperitoneal lymph-node dissection after adjuvant therapy: different indications.
    Minerva Urol Nefrol. 2017;69:153-158.
    Abstract    

    Abstract available

  67. SORIA F, Shariat SF, Lerner SP, Fritsche HM, et al
    Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC).
    World J Urol. 2017;35:379-387.
    Abstract    

    Abstract available

  68. HAYAKAWA M, Kodama M, Sato S, Tomoeda-Mori K, et al
    Electrochemical telomerase assay for screening for oral cancer.
    Br J Oral Maxillofac Surg. 2016 Jan 25. pii: S0266-4356(16)00005.
    Abstract    

    Abstract available

  69. SKRZYPCZYK MA, Nyk L, Szostek P, Szemplinski S, et al
    The role of endoscopic bladder tumour assessment in the management of patients subjected to transurethral bladder tumour resection.
    Eur J Cancer Care (Engl). 2017;26.
    Abstract    

    Abstract available

  70. FANG Y, Wolfson B, Godbey WT
    Non-invasive Detection of Bladder Cancer via Expression-targeted Gene Delivery.
    J Gene Med. 2017 Oct 11. doi: 10.1002/jgm.2992.
    Abstract    

    Abstract available

  71. NAZARI A, Khorramdelazad H, Hassanshahi G
    Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
    Int J Clin Oncol. 2017 Oct 11. doi: 10.1007/s10147-017-1187.
    Abstract    

    Abstract available

  72. MITASH N, Agnihotri S, Tiwari S, Agrawal V, et al
    MicroRNA-21 could be a molecular marker to predict the recurrence of nonmuscle invasive bladder cancer.
    Indian J Urol. 2017;33:283-290.
    Abstract    

    Abstract available

  73. THOMA C
    Bladder cancer: Combination therapy effective in advanced disease.
    Nat Rev Urol. 2017 Oct 10. doi: 10.1038/nrurol.2017.
    Abstract    



  74. THOMA C
    Bladder cancer: Benefit of adjuvant chemotherapy in UTUC unclear.
    Nat Rev Urol. 2017 Oct 10. doi: 10.1038/nrurol.2017.
    Abstract    



  75. STONE L
    Bladder cancer: Mastering the immune microenvironment.
    Nat Rev Urol. 2017 Oct 10. doi: 10.1038/nrurol.2017.
    Abstract    



  76. AHAMAD A, Martinez A, Salenius S, Ross R, et al
    Routine bladder cancer treatment dictates divergence from trial-derived regimens: Results of treatment at 44 radiotherapy centers.
    Urol Oncol. 2017 Oct 6. pii: S1078-1439(17)30473.
    Abstract    

    Abstract available

  77. WU X, Yan T, Wang Z, Wu X, et al
    LncRNA ZEB2-AS1 promotes bladder cancer cell proliferation and inhibits apoptosis by regulating miR-27b.
    Biomed Pharmacother. 2017;96:299-304.
    Abstract    

    Abstract available

  78. AUGUSTIN LSA, Taborelli M, Montella M, Libra M, et al
    Associations of dietary carbohydrates, glycaemic index and glycaemic load with risk of bladder cancer: a case-control study.
    Br J Nutr. 2017 Oct 9:1-8. doi: 10.1017/S0007114517002574.
    Abstract    

    Abstract available

  79. CHEN L, Yuan L, Wang G, Cao R, et al
    Identification and bioinformatics analysis of miRNAs associated with human muscle invasive bladder cancer.
    Mol Med Rep. 2017 Oct 4. doi: 10.3892/mmr.2017.7726.
    Abstract    

    Abstract available

  80. ROBERTSON AG, Kim J, Al-Ahmadie H, Bellmunt J, et al
    Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.
    Cell. 2017 Oct 4. pii: S0092-8674(17)31056-5. doi: 10.1016/j.cell.2017.
    Abstract    

    Abstract available

  81. WOO S, Suh CH, Kim SY, Cho JY, et al
    Diagnostic performance of MRI for prediction of muscle-invasiveness of bladder cancer: A systematic review and meta-analysis.
    Eur J Radiol. 2017;95:46-55.
    Abstract    

    Abstract available

  82. PIETERS BR, van der Steen-Banasik E, Smits GA, De Brabandere M, et al
    GEC-ESTRO/ACROP recommendations for performing bladder-sparing treatment with brachytherapy for muscle-invasive bladder carcinoma.
    Radiother Oncol. 2017;122:340-346.
    Abstract    

    Abstract available

  83. FEDERICO A, Zappavigna S, Dallio M, Misso G, et al
    Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors.
    Curr Cancer Drug Targets. 2017;17:109-121.
    Abstract    

    Abstract available

  84. NGUYEN VP, Oh J, Park S, Wook Kang H, et al
    Feasibility of photoacoustic evaluations on dual-thermal treatment of ex vivo bladder tumors.
    J Biophotonics. 2017;10:577-588.
    Abstract    

    Abstract available

  85. CALLAHAN S, Kim RH, Brinster N, Latkowski JA, et al
    Kaposi's sarcoma in an HIV-negative patient.
    Dermatol Online J. 2016;22.
    Abstract    

    Abstract available

  86. REN R, Tyryshkin K, Graham CH, Koti M, et al
    Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance.
    Oncotarget. 2017;8:70982-71001.
    Abstract    

    Abstract available

  87. YUAN L, Shu B, Chen L, Qian K, et al
    Overexpression of COL3A1 confers a poor prognosis in human bladder cancer identified by co-expression analysis.
    Oncotarget. 2017;8:70508-70520.
    Abstract    

    Abstract available

  88. LATOSINSKA A, Mokou M, Makridakis M, Mullen W, et al
    Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.
    Oncotarget. 2017;8:69435-69455.
    Abstract    

    Abstract available

  89. QUAN Y, Jeong CW, Kwak C, Kim HH, et al
    Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials.
    Medicine (Baltimore). 2017;96:e8300.
    Abstract    

    Abstract available

  90. MIYAKE M, Tatsumi Y, Gotoh D, Ohnishi S, et al
    Regulatory T Cells and Tumor-Associated Macrophages in the Tumor Microenvironment in Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacille Calmette-Guerin: A Long-Term Follow-Up Study of a Japanese Cohort.
    Int J Mol Sci. 2017;18.
    Abstract    

    Abstract available

  91. NAKAGAWA M, Karashima T, Kamada M, Yoshida E, et al
    Development of a fully automated chemiluminescence immunoassay for urine monomeric laminin-gamma2 as a promising diagnostic tool of non-muscle invasive bladder cancer.
    Biomark Res. 2017;5:29.
    Abstract    

    Abstract available

  92. FENG C, Ho Y, Sun C, Xia G, et al
    Epigallocatechin gallate inhibits the growth and promotes the apoptosis of bladder cancer cells.
    Exp Ther Med. 2017;14:3513-3518.
    Abstract    

    Abstract available

  93. ZHANG B, Wu Z, Xie W, Tian D, et al
    The expression of vasohibin-1 and its prognostic significance in bladder cancer.
    Exp Ther Med. 2017;14:3477-3484.
    Abstract    

    Abstract available

  94. LIU D, Qiu XY, Wu X, Hu DX, et al
    Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization.
    Biochem Biophys Res Commun. 2017 Oct 13. pii: S0006-291X(17)32039.
    Abstract    

    Abstract available

  95. CARAMES MASANA F, de Reijke TM
    The efficacy of Apaziquone in the treatment of bladder cancer.
    Expert Opin Pharmacother. 2017 Oct 20:1-8. doi: 10.1080/14656566.2017.1392510.
    Abstract    

    Abstract available

  96. HOLZ S, Albisinni S, Gilsoul J, Pirson M, et al
    Risk factor assessment in high-risk, bacillus Calmette-Guerin-treated, non-muscle-invasive bladder cancer.
    Res Rep Urol. 2017;9:195-202.
    Abstract    

    Abstract available

  97. SEEGOBIN K, Maharaj S, Baldeo C, Isache C, et al
    Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer.
    IDCases. 2017;10:75-78.
    Abstract    

    Abstract available

  98. SALEHI S, Mansoori B, Mohammadi A, Davoudian S, et al
    An analysis of suppressing migratory effect on human urinary bladder cancer cell line by silencing of snail-1.
    Biomed Pharmacother. 2017;96:545-550.
    Abstract    

    Abstract available

  99. LI Y, Lin K, Yang Z, Han N, et al
    Bladder cancer stem cells: clonal origin and therapeutic perspectives.
    Oncotarget. 2017;8:66668-66679.
    Abstract    

    Abstract available

  100. WANG X, Xu T, Gao F, He H, et al
    Targeting of CCN2 suppresses tumor progression and improves chemo-sensitivity in urothelial bladder cancer.
    Oncotarget. 2017;8:66316-66327.
    Abstract    

    Abstract available

  101. XU L, Li H, Wu L, Huang S, et al
    YBX1 promotes tumor growth by elevating glycolysis in human bladder cancer.
    Oncotarget. 2017;8:65946-65956.
    Abstract    

    Abstract available

  102. KUSAKA A, Hatakeyama S, Hosogoe S, Hamano I, et al
    Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer.
    Oncotarget. 2017;8:65492-65505.
    Abstract    

    Abstract available

  103. POLO A, Crispo A, Cerino P, Falzone L, et al
    Environment and bladder cancer: molecular analysis by interaction networks.
    Oncotarget. 2017;8:65240-65252.
    Abstract    

    Abstract available

  104. VERMA H, Sharma T, Gupta S, Banerjee BD, et al
    CYP1A1 expression and organochlorine pesticides level in the etiology of bladder cancer in North Indian population.
    Hum Exp Toxicol. 2017 Jan 1:960327117734623. doi: 10.1177/0960327117734623.
    Abstract    

    Abstract available

  105. TANG JQ, Zhao Z, Liang Y, Liao G, et al
    Robotic-assisted versus open radical cystectomy in bladder cancer: A meta-analysis of four randomized controlled trails.
    Int J Med Robot. 2017 Oct 12. doi: 10.1002/rcs.1867.
    Abstract    

    Abstract available

  106. WALLIS CJD, Juvet T, Lee Y, Matta R, et al
    Association Between Use of Antithrombotic Medication and Hematuria-Related Complications.
    JAMA. 2017;318:1260-1271.
    Abstract    

    Abstract available

  107. URREA YR, Epstein JI
    Sarcomatoid carcinoma associated with small cell carcinoma of the urinary bladder: a series of 28 cases.
    Hum Pathol. 2017;67:169-175.
    Abstract    

    Abstract available

  108. WANG G, Huang H, Kamat AM, Siefker-Radtke A, et al
    High-grade neuroendocrine carcinoma of the urachus-report of 3 cases.
    Hum Pathol. 2017;67:126-133.
    Abstract    

    Abstract available

  109. GIANNICO GA, Gown AM, Epstein JI, Revetta F, et al
    Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
    Hum Pathol. 2017;67:152-159.
    Abstract    

    Abstract available

  110. DELL'OGLIO P, Tian Z, Leyh-Bannurah SR, Trudeau V, et al
    Short-Form Charlson Comorbidity Index for Assessment of Perioperative Mortality After Radical Cystectomy.
    J Natl Compr Canc Netw. 2017;15:327-333.
    Abstract    

    Abstract available

  111. GOMELLA LG, Mann MJ, Cleary RC, Hubosky SG, et al
    Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.
    Can J Urol. 2017;24:8620-8626.
    Abstract    

    Abstract available

  112. HOLMANG S

    Lakartidningen. 2017;114.
    Abstract    



  113. LLORENTE C, Lopez B, Hernandez V, Guijarro A, et al
    Variability in complications and operative mortality after radical cystectomy in Spain.
    Actas Urol Esp. 2017;41:32-38.
    Abstract    

    Abstract available

  114. SHARMA P, Zargar-Shoshtari K, Poch MA, Pow-Sang JM, et al
    Surgical control and margin status after robotic and open cystectomy in high-risk cases: Caution or equivalence?
    World J Urol. 2017;35:657-663.
    Abstract    

    Abstract available

  115. PACKIAM VT, Agrawal VA, Pariser JJ, Cohen AJ, et al
    Redefining the implications of nasogastric tube placement following radical cystectomy in the alvimopan era.
    World J Urol. 2017;35:625-631.
    Abstract    

    Abstract available

  116. HAKOZAKI K, Kikuchi E, Fukumoto K, Shirotake S, et al
    Significance of a frozen section analysis of the ureteral margin in bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapy.
    Med Oncol. 2017;34:187.
    Abstract    

    Abstract available

  117. GIRIDHAR KV, Kohli M
    Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer.
    Mayo Clin Proc. 2017;92:1564-1582.
    Abstract    

    Abstract available

  118. BORHAN WM, Cimino-Mathews AM, Montgomery EA, Epstein JI, et al
    Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder.
    Am J Surg Pathol. 2017;41:1570-1575.
    Abstract    

    Abstract available

  119. UEMURA K, Namura K, Umemoto S, Matsubara O, et al
    [A Case of Squamous Cell Carcinoma in Bladder Diverticulum Producing Granulocyte Colony Stimulating Factor].
    Hinyokika Kiyo. 2017;63:211-215.
    Abstract    

    Abstract available

  120. BI X, Wu Z, Han H, Zhou F, et al
    Clinical comparison of patients with benign urachal masses versus urachal carcinomas.
    Chin J Cancer. 2017;36:2.
    Abstract    

    Abstract available

  121. KHORRAMI MH, Javid A, Izadpanahi MH, Alizadeh F, et al
    Efficacy of Long-Acting Octreotide on Reducing Mucus Production in Patients With Ileal Neobladder.
    Clin Genitourin Cancer. 2017;15:e9-e13.
    Abstract    

    Abstract available

  122. MONN MF, Jaqua KR, Bihrle R, Cheng L, et al
    Primary Choriocarcinoma of the Bladder: A Case Report and Review of Literature.
    Clin Genitourin Cancer. 2017;15:188-191.
    Abstract    

    Abstract available

  123. CARAS RJ, Lustik MB, Kern SQ, McMann LP, et al
    Preoperative Albumin Is Predictive of Early Postoperative Morbidity and Mortality in Common Urologic Oncologic Surgeries.
    Clin Genitourin Cancer. 2017;15:e255-e262.
    Abstract    

    Abstract available

  124. SINGH R, Ansari JA, Maurya N, Mandhani A, et al
    Epithelial-To-Mesenchymal Transition and Its Correlation With Clinicopathologic Features in Patients With Urothelial Carcinoma of the Bladder.
    Clin Genitourin Cancer. 2017;15:e187-e197.
    Abstract    

    Abstract available

  125. BACH T, Bastian PJ, Blana A, Kaminsky A, et al
    Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III.
    World J Urol. 2017;35:737-744.
    Abstract    

    Abstract available

  126. MOSCHINI M, Soria F, Klatte T, Wirth GJ, et al
    Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy.
    Clin Genitourin Cancer. 2017;15:e267-e273.
    Abstract    

    Abstract available

  127. AIZAWA R, Sakamoto M, Orito N, Kono M, et al
    The Use of External-beam Radiotherapy for Muscle-invasive Bladder Cancer in Elderly or Medically-fragile Patients.
    Anticancer Res. 2017;37:5761-5766.
    Abstract    

    Abstract available

  128. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Radical Cystectomy Versus Chemoradiation for Muscle-invasive Bladder Cancer: Impact of Treatment Facility and Sociodemographics.
    Anticancer Res. 2017;37:5603-5608.
    Abstract    

    Abstract available

  129. D'ANDREA D, Moschini M, Soria F, Gust KM, et al
    ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder.
    Anticancer Res. 2017;37:5747-5753.
    Abstract    

    Abstract available

  130. SCHINZARI G, Monterisi S, Pierconti F, Nazzicone G, et al
    Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
    Anticancer Res. 2017;37:6453-6458.
    Abstract    

    Abstract available

  131. PICHLER R, Fritz J, Tulchiner G, Klinglmair G, et al
    Increased Accuracy of a novel mRNA-based Urine Test for Bladder Cancer Surveillance.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14019.
    Abstract    

    Abstract available

  132. SMITH AB, Jaeger B, Pinheiro LC, Edwards LJ, et al
    The impact of bladder cancer on health-related quality of life.
    BJU Int. 2017 Oct 8. doi: 10.1111/bju.14047.
    Abstract    

    Abstract available

  133. XIA L, Taylor BL, Newton AD, Malhotra A, et al
    Early Discharge and Post-Discharge Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer.
    BJU Int. 2017 Oct 24. doi: 10.1111/bju.14058.
    Abstract    

    Abstract available

  134. AHMADI N, Clifford TG, Miranda G, Cai J, et al
    Impact of body mass index on robot-assisted radical cystectomy with intracorporeal urinary diversion.
    BJU Int. 2017;120:689-694.
    Abstract    

    Abstract available

  135. HUDDART RA, Birtle A, Maynard L, Beresford M, et al
    Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
    BJU Int. 2017;120:639-650.
    Abstract    

    Abstract available

  136. MORERA DS, Hennig MS, Talukder A, Lokeshwar SD, et al
    Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    Abstract    

    Abstract available

  137. SELINSKI S, Blaszkewicz M, Ickstadt K, Gerullis H, et al
    Identification and replication of the interplay of four genetic high risk variants for urinary bladder cancer.
    Carcinogenesis. 2017 Sep 27. doi: 10.1093.
    Abstract    

    Abstract available

  138. SORIA F, Marra G, Capoun O, Soukup V, et al
    Prevention of bladder cancer incidence and recurrence: tobacco use.
    Curr Opin Urol. 2017 Oct 3. doi: 10.1097/MOU.0000000000000453.
    Abstract    

    Abstract available

  139. MARI A, Abufaraj M, Gust KM, Shariat SF, et al
    Novel endoscopic visualization techniques for bladder cancer detection: a review of the contemporary literature.
    Curr Opin Urol. 2017 Oct 17. doi: 10.1097/MOU.0000000000000459.
    Abstract    

    Abstract available

  140. BIRKENKAMP-DEMTRODER K, Christensen E, Nordentoft I, Knudsen M, et al
    Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30775.
    Abstract    

    Abstract available

  141. OHNO Y
    Re: Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer.
    Eur Urol. 2017 Sep 26. pii: S0302-2838(17)30780.
    Abstract    



  142. RAVA M, Czachorowski MJ, Silverman D, Marquez M, et al
    Asthma status is associated with decreased risk of aggressive urothelial bladder cancer.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31066.
    Abstract    

    Abstract available

  143. YAMASHITA R, Watanabe R, Ito I, Shinsaka H, et al
    Risk factors for intravesical recurrence after nephroureterectomy in patients with upper urinary tract urothelial carcinoma.
    Int Urol Nephrol. 2017;49:425-430.
    Abstract    

    Abstract available

  144. RYAN S, Serrell EC, Karabon P, Mills G, et al
    The Association Between Mortality and Distance to Treatment Facility in Patients with Muscle Invasive Bladder Cancer.
    J Urol. 2017 Oct 10. pii: S0022-5347(17)77715-4. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  145. WALLACE E, Higuchi R, Satya M, McCann L, et al
    Development of a 90-minute integrated non-invasive urinary assay for bladder cancer detection.
    J Urol. 2017 Oct 20. pii: S0022-5347(17)77760-9. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  146. ATALA A
    Re: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
    J Urol. 2017;198:985.
    Abstract    



  147. ATALA A
    Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2.
    J Urol. 2017;198:984-985.
    Abstract    



  148. ATALA A
    Re: Profiling of Long Non-Coding RNAs Identifies LINC00958 and LINC01296 as Candidate Oncogenes in Bladder Cancer.
    J Urol. 2017;198:983-985.
    Abstract    



  149. CHANG SS
    Re: Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-Muscle Invasive Bladder Cancer Patients.
    J Urol. 2017;198:979-980.
    Abstract    



  150. CHANG SS
    Re: Anti-Inflammatory Use May Not Negatively Impact Oncologic Outcomes following Intravesical BCG for High-Grade Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2017;198:978-980.
    Abstract    



  151. ZHAO X, Ji Z, Xie Y, Liu G, et al
    MicroRNA-154 as a prognostic factor in bladder cancer inhibits cellular malignancy by targeting RSF1 and RUNX2.
    Oncol Rep. 2017 Sep 25. doi: 10.3892/or.2017.5992.
    Abstract    

    Abstract available

  152. HUANG B, Zhang J, Zhang X, Huang C, et al
    Suppression of LETM1 by siRNA inhibits cell proliferation and invasion of bladder cancer cells.
    Oncol Rep. 2017 Sep 18. doi: 10.3892/or.2017.5959.
    Abstract    

    Abstract available

  153. KOU B, Liu W, Xu X, Yang Y, et al
    Autophagy induction enhances tetrandrine-induced apoptosis via the AMPK/mTOR pathway in human bladder cancer cells.
    Oncol Rep. 2017 Sep 21. doi: 10.3892/or.2017.5988.
    Abstract    

    Abstract available

  154. KISS B, Thoeny HC, Studer UE
    Current Status of Lymph Node Imaging in Bladder and Prostate Cancer.
    Urology. 2016 Mar 7. pii: S0090-4295(16)00182.
    Abstract    

    Abstract available

  155. DAI YC, Wang SC, Haque MM, Lin WH, et al
    The interaction of arsenic and N-butyl-N-(4-hydroxybutyl)nitrosamine on urothelial carcinogenesis in mice.
    PLoS One. 2017;12:e0186214.
    Abstract    

    Abstract available

  156. HUANG JY, Wang R, Gao YT, Yuan JM, et al
    ABO blood type and the risk of cancer - Findings from the Shanghai Cohort Study.
    PLoS One. 2017;12:e0184295.
    Abstract    

    Abstract available

  157. KWAK YK, Lee SW, Kay CS, Park HH, et al
    Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose.
    PLoS One. 2017;12:e0183339.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;